Focal therapy of prostate and kidney cancer

Abstract

We are delighted to present this special issue of ‘Current Opinion in Urology’ addressing several contemporary topics of focal therapy for prostate and kidney cancers. Over the past two decades, we have observed the changing landscape of prostate cancer and renal tumors. In the era of prostate cancer screening, there has been a stage migration and shift toward smallvolume low-to-intermediate-risk prostate cancer [1]. Although radical treatment is still the most common management strategy for localized prostate cancer, its associated comorbidities remain a great concern to patients [2,3]. Active surveillance, on the other end of the spectrum, is the least invasive management strategy for low-risk to some favorable intermediate-risk prostate cancers. However, as many as 20% of patients under active surveillance protocols may ultimately select radical treatment because of disease reclassification and/or patient anxiety.